Table 2.
A summary of organic-mercury exposure from Thimerosal-containing hepatitis B vaccine administration among ASD cases and controls in the VSD database
| Group examined | Number of cases diagnosed with ASD (%) | Number of controls without an ASD (%) | Odds ratio (95% CI) | p-value |
|---|---|---|---|---|
|
Experiment I
|
|
|
|
|
| 12.5 μg organic-mercury within 1st month |
155 (50.49) |
8,161 (31.84) |
|
|
| |
|
|
2.18 (1.74–2.73) |
< 0.00001 |
| 0 μg organic mercury within 1st month |
152 (49.51) |
17,471 (68.16) |
|
|
|
Experiment II
|
|
|
|
|
| 25 μg organic-mercury within first 2 months |
154 (50.49) |
8,172 (32.55) |
|
|
| |
|
|
2.11 (1.68–2.64) |
< 0.0001 |
| 0 μg organic-mercury within first 2 months |
151 (49.51) |
16,935 (67.45) |
|
|
|
Experiment III
|
|
|
|
|
| 37.5 μg organic-mercury within first 6 months |
30 (76.92) |
1,073 (49.54) |
|
|
| |
|
|
3.39 (1.60–7.18) |
< 0.001 |
| 0 μg organic-mercury within first 6 months | 9 (23.08) | 1,093 (50.46) |